Emily’s Entourage (EE) provides critical funding to accelerate research and drug development for individuals in the final 10% of the CF community that do not benefit from existing CFTR modulators, including those with rare and nonsense mutations.
To date, EE has awarded grants to researchers from around the world and helped to secure millions of dollars in follow-on funding. The research projects funded by EE have made significant progress in advancing therapeutic development with a number of projects currently advancing to the preclinical stage.
EE provides funding through several grant funding mechanisms.
Translational Grants
EE’s Translational Grant Program provides critical seed funding to innovative investigators with promising strategies that accelerate research and drug development for those in the final 10% of the CF community who do not benefit from CFTR modulators, including those with rare and nonsense mutations.
Support is available for $100,000 per year (plus 10% for indirect costs). Typically, funding is for two years. Continuation of funding is contingent on progress, which is reported every six months. Learn more about EE’s Translational Grant Program.
Collaborative Grants
EE’s Collaborative Grants support research projects that bring together multiple investigators with diverse areas of expertise to jointly tackle challenges in the development of therapeutics for individuals in the final 10% of the CF community who do not benefit from CFTR modulators, including those with rare and nonsense mutations.
These grants are awarded to teams of three or more investigators with complementary expertise to advance therapeutic development in ways that could not be achieved without a collaborative approach. The funding amount is determined by the project scope and budget. Applicants may request funding to support the project for a total of three years. Learn more about EE’s Collaborative Grants.
Venture Philanthropy Investments
In addition to providing grants, EE also advances research and therapeutic development with strategic investments made through a venture philanthropy model. Using this entrepreneurial approach, EE provides early-stage funding to companies to expedite the development of promising therapies and a cure for people with CF who do not benefit from the currently available CFTR modulator therapies. Learn more about EE’s venture philanthropy investments.